The U.S. Food and Drug Administration (FDA) has until the end of the month to decide if it will allow OpenBiome, the ...

In fact, after a successful first-line treatment with standard therapies, metronidazole or vancomycin, 20–30% of patients may experience a second event within 60 days from discontinuation ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

[43] Fewer treatment failures occurred with vancomycin use, but the difference was not significant. Relapse rates were also similar between treatment groups. Cost differences should be considered ...

An innovative treatment for debilitating and often deadly cases of recurrent C diff infection has been given a Breakthrough Therapy Designation by the FDA. Developed by US biotech firm Rebiotix ...

Ferring Pharmaceuticals today announced three poster presentations at the American College of Gastroenterology’s annual ...

Just as modern vaccines evolved from cowpox blisters and penicillin from moldy bread, another life-saving treatment is ...

22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in ...

As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding ...

difficile infection. The company’s phase 2 clinical trial testing ibezapolstat treatment of C. diff infection (CDI) in the second half of 2023 surprised investors which more than tripled the ...